The Fairholme Focused Income Fund Announces Dividend

MIAMI--(BUSINESS WIRE)-- On June 24, 2022, the Fairholme Focused Income Fund (“FOCIX” or the “Fund”) distributed an Ordinary Income dividend of $0.05631 per share to shareholders of record as of June 23, 2022. The Fund’s Net Asset Value (“NAV”) was reduced by the amount of the distribution.

The Record Date, Ex-Dividend Date, Payable Date, and Cents-Per-Share are as follows:

Past performance is not a guarantee of future results.

The Fund’s investment objectives, risks, charges, and expenses should be considered carefully before investing. The prospectus contains this and other important information about the Fund, and it may be obtained by calling Shareholder Services at (866) 202-2263 or visiting our website www.fairholmefunds.com. Read it carefully before investing.

Investing in the Fund involves risk including loss of principal. The Fund is a non-diversified mutual fund, which means that the Fund invests in a smaller number of securities when compared to more diversified funds. This strategy exposes the Fund and its shareholders to greater risk of loss from adverse developments affecting portfolio companies. The Fund’s investments are also subject to interest rate risk, which is the risk that the value of a security will decline because of a change in general interest rates. Investments subject to interest rate risk will usually decrease in value when interest rates rise and rise in value when interest rates decline. Also, securities with long maturities typically experience a more pronounced change in value when interest rates change. Debt securities are subject to credit risk (potential default by the issuer). The Fund may invest without limit in lower-rated securities. Compared to higher-rated fixed income securities, lower-rated debt may entail greater risk of default and market volatility.

Foreside Funds Distributors LLC (6/22)

View source version on businesswire.com: https://www.businesswire.com/news/home/20220624005446/en/

Fairholme Funds, Inc.
Jodi Lin, 305-358-3000

Source: Fairholme Funds, Inc.

You May Also Be Interested In

• FairJourney Bio Delivers Antibody Engineering for Novel Tumor-Conditional IL-12 Therapeutic Approach That Unlocks the Potential of Localized Cytokine Activation
• Invitation to Minesto's webinar: Q2 update by CEO
• Grande Portage Resources Receives State of Alaska Regulatory Clearance for Road Easement